View Author
patient myeloma bortezomib therapy dexamethasone study response treatment thalidomide lenalidomide trial blood survival phase cancer disease combination group result analysis factor table month cycle regimen myeloma patients transplantation signi agent neuropathy grade university high-dose serum leukemia protein ef ficacy tipifarnib cell transplantation signi ficantly response rate event outcome randomized effect number richardson hospital melphalan len /dex reduction progression novel agents incidence novel doxorubicin cytogenetic department induction prognostic marker oncol level high-dose dexamethasone celgene marrow cyclophosphamide autologou journal chemotherapy prednisone hematology prophylaxi ficacy fication high-dose therapy erasmus mc relapse impact bene fit
10 Most Recent Publications
|
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression
(Article)
Shah, J. Bladé, J. Sonneveld, P. Harousseau, J-L. Lantz, K. Londhe, A. Lowery, C. Orlowski, R.Z. |
2011-08-15
|
|
Multiple myeloma treatment strategies with novel agents in 2011: A European perspective
(Article)
Ludwig, H. Beksaç, M. Goldschmidt, H. Harousseau, J-L. Hess, U. Kropff, M. Da Costa, F.L. Louw, V. Magen-Nativ, H. Mendeleeva, L. Nahi, H. Plesner, T. Bladé, J. San Miguel, J. Sonneveld, P. Udvardy, M. Sondergeld, P. Palumbo, A. Cavenagh, J. Cavo, M. Delforge, M. Dimopoulos, M.A. Drach, J. Einsele, H. Facon, T. |
2011-05-06
|
|
Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
(Article)
Munshi, N.C. Anderson, K.C. Jagannath, S. Hajek, R. Sezer, O. Kyle, R. Sonneveld, P. Cavo, M. Rajkumar, S.V. San-Miguel, J-F. Crowley, J. Avet-Loiseau, H. Bergsagel, P.L. Shaughnessy, J. Palumbo, A. Durie, B.G.M. Fonseca, R. Stewart, A.K. Harousseau, J-L. Dimopoulos, M.A. |
2011-05-05
|
|
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement
(Article)
Dimopoulos, M.A. Palumbo, A. Ludwig, H. Mellqvist, U.H. Morgan, G. San Miguel, J-F. Zweegman, S. Sonneveld, P. Attal, M. Beksaç, M. Davies, F. Delforge, M. Einsele, H. Hajek, R. Harousseau, J-L. Da Costa, F.L. |
2011-05-01
|
|
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
(Article)
Buda, G. Ricci, D. Huang, C.C. Favis, R. Cohen, N. Zhuang, S.H. Harousseau, J-L. Sonneveld, P. Bladé, J. Orlowski, R.Z. |
2010-11-01
|
|
The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group
(Article)
Terpos, E. Dimopoulos, M.A. Palumbo, A. Sonneveld, P. Drake, M.T. Harousseau, J-L. Anderson, K.C. Durie, B.G.M. Sezer, O. Roodman, D. Abildgaard, N. Vescio, R. Tosi, P. Garcia-Sanz, R. Davies, F. Chanan-Khan, A. |
2010-10-01
|
|
Current multiple myeloma treatment strategies with novel agents: A European perspective
(Article)
Ludwig, H. Beksac, M. Goldschmidt, H. Harousseau, J-L. Hess, U. Ketterer, N. Kropff, M. Mendeleeva, L. Morgan, G. Palumbo, A. Plesner, T. San Miguel, J-F. Bladé, J. Shpilberg, O. Sondergeld, P. Sonneveld, P. Zweegman, S. Boccadoro, M. Cavenagh, J. Cavo, M. Dimopoulos, M.A. Drach, J. Einsele, H. Facon, T. |
2010-02-05
|
|
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
(Article)
Kumar, S. Giralt, S. Miguel, J.S. Ludwig, H. Bergsagel, L. Bladé, J. Lonial, S. Anderson, K.C. Tosi, P. Sonneveld, P. Sezer, O. Vesole, D. Stadtmauer, E.A. Cavo, M. Einsele, H. Richardson, P.G. Durie, B.G.M. Rajkumar, S.V. Harousseau, J-L. Palumbo, A. Bensinger, W. Comenzo, R.L. Lentzsch, S. Munshi, N.C. Niesvizky, R. |
2009-11-20
|
|
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
(Article)
Vogl, D.T. Stadtmauer, E.A. Anderson, K.C. Richardson, P.G. Sonneveld, P. Schuster, M.W. Irwin, D. Facon, T. Harousseau, J-L. Boral, A.L. Neuwirth, R. |
2009-11-01
|
|
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
(Article)
Giralt, S. Stadtmauer, E.A. Merlini, G. San Miguel, J. Ludwig, H. Hajek, R. Jagannath, S. Blade, J. Lonial, S. Dimopoulos, M.A. Einsele, H. Barlogie, B. Harousseau, J-L. Anderson, K.C. Gertz, M. Attal, M. Tosi, P. Sonneveld, P. Boccadoro, M. Morgan, G. Sezer, O. Mateos, M.V. Cavo, M. Palumbo, A. Joshua, D. Turesson, I. Chen, W. Shimizu, K. Powles, R. Richardson, P.G. Niesvizky, R. Rajkumar, S.V. Durie, B.G.M. Bensinger, W. Comenzo, R.L. Kumar, S. Munshi, N.C. Dispenzieri, A. Kyle, R. |
2009-06-26
|
